Waystar (WAY) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary
Event summary combining transcript, slides, and related documents.
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary
2 Feb, 2026Key business highlights
Achieved 20% year-over-year revenue growth and 12% EBITDA growth in Q2, with strong free cash flow.
Completed a successful IPO and celebrated team contributions.
Operates a recurring revenue model with high visibility and durability.
Targets low double-digit revenue growth and 40% adjusted EBITDA margin.
De-levered to a 3.4x leverage ratio post-IPO, with plans to reduce further.
Product and technology differentiation
Offers a modern, multi-tenant, cloud-based platform with AI-driven automation and intuitive UI.
Addresses a $15B and growing market by simplifying provider-payer and provider-patient payment interactions.
Delivers nearly 99% first-pass claim acceptance, reducing denials and accelerating payments.
Provides in-app training, task prioritization, and knowledge retention to improve staff efficiency.
Integrates with over 200 channel partners, including major EHR vendors.
Cybersecurity and market impact
Benefited from the Change Healthcare cyberattack by onboarding over 30,000 providers on standard, multi-year agreements.
Demonstrates strong cybersecurity credentials (HITRUST, SOC 2, NIST 2.0) and rapid restoration capabilities.
Cybersecurity is now a top decision criterion for clients, driving technology replacement and platform adoption.
Multi-factor authentication and end-to-end encryption are standard.
Platform approach reduces risk compared to fragmented point solutions.
Latest events from Waystar
- Record FY2025 growth, 43% Q4 EBITDA margin, and strong 2026 outlook with AI momentum.WAY
Q4 202517 Feb 2026 - AI-powered automation streamlines healthcare payments, boosting efficiency and financial outcomes.WAY
Waystar True North Client Conference3 Feb 2026 - Q2 revenue up 20% to $234.5M, 40% EBITDA margin, and improved leverage ratios.WAY
Q2 20242 Feb 2026 - Q3 revenue up 22% to $240.1M, 40% EBITDA margin, and major debt reduction post-IPO.WAY
Q3 202416 Jan 2026 - AI-driven automation and data integration fuel growth, efficiency, and client satisfaction.WAY
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026 - Cloud-based healthcare payment software drives growth, efficiency, and resilience in a shifting market.WAY
7th Annual Evercore ISI HealthCONx Healthcare Conference11 Jan 2026 - Strong Q3 growth, durable revenue, and 40% EBITDA margins drive market share gains.WAY
Barclays 22nd Annual Global Technology Conference 202411 Jan 2026 - AI-driven healthcare payment automation accelerates growth, efficiency, and industry leadership.WAY
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - 2024 revenue up 19% with strong margins; 2025 guidance targets 7–10% growth and ongoing innovation.WAY
Q4 20246 Jan 2026